Incretin hormones

Česká verzia

Authors: J. Čáp
Authors place of work: II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
Published in the journal: Vnitř Lék 2011; 57(4): 405-410
Category: 12th national Symposium diabetes, "Diabetes and Gastroenterology", Hradec Kralove, 4 to 5 June 2010

Summary

Incretin hormones are peptides that are secreted from endocrine cell of gastrointestinal tract after nutrient ingestion and stimulate insulin secretion. Glucosodependent Insulinotropic Peptide – GIP is released from K-cells of duodenum and proximal jejunum, recently GIP synthesis has been proved in pancreatic α cells. Besides the incretin effect causes GIP increased lipogenesis and decreased lipolysis in fat tissue, increased bone formation and decreased resorption and has protective and proliferative effect on CNS neurons. Both GIP agonists (to treat diabetes) and antagonist (to treat obesity) are being studied. Another incretin hormone is derived in intestinal l-cells by posttranslational processing of proglucagon – glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). GLP-1 stimulates insuline production and inhibits glucagon secretion, exerts proliferative and antiapoptotic effect on β-cells. Via receptors on vagal nerve and central mechanisms decreases food intake and decreases body weight. By deceleration of gastric emptying it attenuates increases in meal-associated blood glucose levels. It exerts cardioprotective effects. GLP-1 receptors have been proved in liver recently but decreased liver glucose production and increased glucose uptake by liver and muscle are mediated indirectly by altering insulin and glucagons levels. GLP-2 stimulates enterocytes proliferation, up-regulates intestinal nutrient transport, improves intestinal barrier function, and inhibits gastric and intestinal motility. GLP-2 also reduces bone resorption.

Key words:
incretin hormones – GIP – GLP-1 – GLP-2

Zdroje

1. Bayliss WM, Starling EH. On the causation of the so-called “peripheral reflex secretion” of the pancreas. Proceedings of the Royal Society of London (Biol) 1902; 69: 352–353.

2. Edie ES. Further Observations on the Treatment of Diabetes Mellitus by Acid Extract of Duodenal Mucous Membrane. Biochem J 1906; 1: 446–454.

3. La Barre J. Sur les possibilites d’un traitement du diabete par l’incretine. Bull Acad R Med Belg 1932; 12: 620–634.

4. McIntyre N, Holdsworth CD, Turner DS. New Interpretation of Oral Glucose Tolerance. Lancet 1964; 2: 20–21.

5. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965; 25: 1317–1324.

6. Mortensen K, Christensen LL, Holst JJ et al. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003; 114: 189–196.

7. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131–2157.

8. Fujita Y, Wideman RD, Asadi A et al. Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 2010; 138: 1966–1975.

9. Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheime’s disease? Expert Opin Investig Drugs 2010; 19: 1039–1048.

10. Flatt PR. Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes? Diabet Med 2008; 25: 759–764.

11. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009; 52: 1724–1731.

12. Walsh JS, Henriksen DB. Feeding and bone. Arch Biochem Biophys 2010; 503: 11–19.

13. Nyberg J, Anderson MF, Meister B et al. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 2005; 25: 1816–1825.

14. Nyberg J, Jacobsson C, Anderson MF et al. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res 2007; 85: 2099–2119.

15. Figueiredo CP, Pamplona FA, Mazzuco TL et al. Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases. Behav Pharmacol 2010; 21: 394–408.

16. Wynne K, Park AJ, Small CJ et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30: 1729–1736.

17. Theodorakis MJ, Carlson O, Michopoulos S et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006; 290: E550–E559.

18. Herrmann C, Göke R, Richter G et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117–126.

19. Deacon CF, Nauck MA, Toft-Nielsen M et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126–1131.

20. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409–1439.

21. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612–615.

22. Vilsbøll T, Krarup T, Deacon CF et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609–613.

23. Alarcon C, Wicksteed B, Rhodes CJ. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 2006; 49: 2920–2929.

24. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239–1246.

25. Li Y, Hansotia T, Yusta B et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471–478.

26. Lavine JA, Attie AD. Gastrointestinal hormones and the regulation of beta-cell mass. Ann N Y Acad Sci 2010; 1212: 41–58.

27. Szayna M, Doyle ME, Betkey JA et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936–1941.

28. Perry T, Haughey NJ, Mattson MP et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002; 302: 881–888.

29. During MJ, Cao L, Zuzga DS et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173–1179.

30. Nicolaus M, Brödl J, Linke R et al. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 2011; 96: 229–236.

31. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005; 21: 91–117.

32. Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955–961.

33. Zhao T, Parikh P, Bhashyam S et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317: 1106–1113.

34. Papazafiropoulou A, Pappas SI, Papadogiannis D et al. Cardiovascular effects of glucagon-like peptide 1. Mini Rev Med Chem 2011; 11: 97–105.

35. Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962–965.

36. Halbirk M, Nørrelund H, Møller N et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010; 298: H1096–H1102.

37. Abu-Hamdah R, Rabiee A, Meneilly GS et al. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009; 94: 1843–1852.

38. Gupta NA, Mells J, Dunham RM et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584–1592.

39. Ding X, Saxena NK, Lin S et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173–181.

40. MacLusky NJ, Cook S, Scrocchi L et al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000; 141: 752–762.

41. Gutzwiller JP, Tschopp S, Bock A et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055–3061.

42. Guan X, Karpen HE, Stephens J et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130: 150–164.

43. Hsieh J, Longuet C, Maida A et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 2009; 137: 997–1005.

44. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005; 1: 22–31.

45. Redstone HA, Buie WD, Hart DA et al. The effect of glucagon-like Peptide-2 receptor agonists on colonic anastomotic wound healing. Gastroenterol Res Pract 2010; doi 10.1155/2010/672453.

46. Yazbeck R. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. Curr Opin Mol Ther 2010; 12: 798–809.

47. Henriksen DB, Alexandersen P, Hartmann B et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009; 45: 833–842.